Abstract 203P
Background
The interaction between the immune system and the tumor microenvironment significantly impacts cancer progression and treatment response. Macrophages, with their diverse functional states, play a crucial role in this interplay. Identifying accurate markers for macrophage infiltration is vital for understanding their roles and therapeutic potential.
Methods
Immunai addresses this challenge by developing single cell atlases. Employing state-of-the-art single cell RNA sequencing (scRNA-seq) technologies, Immunai generates comprehensive and high-resolution transcriptomics data from diverse tumor samples, encompassing a wide range of cancer types. The establishment of scRNA-seq data atlases and references enables the identification of distinct macrophage populations within the tumor microenvironment, as well as their heterogeneity and functional states. Utilizing advanced computational algorithms and analytical pipelines, Immunai systematically analyses scRNA-seq datasets to uncover specific molecular signatures associated with macrophage infiltration.
Results
In the presented work, Immunai's approach enabled the discovery of novel macrophage-specific markers that can serve as valuable tools for both basic research and clinical applications. The identified markers offer insights into the dynamic nature of macrophage populations within the tumor microenvironment and provide potential avenues for the development of immunotherapies targeting tumor-associated macrophages. Moreover, these markers hold promise as diagnostic and prognostic indicators, aiding in patient stratification and personalized treatment strategies.
Conclusions
Immunai's approach provides a significant contribution to immuno-oncology and novel therapeutic approaches.
Legal entity responsible for the study
Immunai.
Funding
Immunai.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
179P - Integrating multiplex immunofluorescence with gene expression data in the IMMUcan HER2-positive breast cancer cohort
Presenter: Mattia Rediti
Session: Poster Display
181P - Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer
Presenter: Jitka Palich Fucikova
Session: Poster Display
182P - Exploring Cross-Compartmental Tumor Cell Plasticity and Immunogenicity in Serous Ovarian Cancer
Presenter: Louisa Hell
Session: Poster Display
183P - Multi-omics Investigation Reveals Cancer-Associated Fibroblast-Secreted FGF7 as an Ovarian Cancer Progression Promoter through HIF-1_/EMT Modulation
Presenter: Songwei Feng
Session: Poster Display
184P - Elevated baseline circulating IL-8 is associated with increased expression of the IMmotion myeloid gene signature (GS) in metastatic clear cell renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (nivo) within the NIVOREN GETUG-AFU 26 study.
Presenter: LUCIA CARRIL AJURIA
Session: Poster Display
185P - The Immunosuppressive Landscape of Leukemia Inhibitory Factor (LIF) in Clear Cell Renal Cell Carcinoma
Presenter: Yazan Al Zu’bi
Session: Poster Display
186P - Post-anti-PD1 tumor characterization of HPV-negative R/M SCCHN: an EORTC IMMUcan sub-project
Presenter: Athénaïs Van Der Elst
Session: Poster Display
187P - Local and systemic anti-tumor response during tumor development in an immune privileged site: the case of uveal melanoma
Presenter: Francesca Lucibello
Session: Poster Display
188P - Expression of the co-stimulatory checkpoint protein OX40L (TNFSF4) in the melanoma micro-environment
Presenter: Raya Leibowitz-Amit
Session: Poster Display